Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Tsolakis A, Kanakis G, Grimelius G, Papaioannou D, Kaltsas G,
Introduction: Several studies have shown altered expression of Insulin-like Growth Factor-1 (IGF-1) and its receptor (IGF-1R) in different types of cancers. Connective Tissue Growth Factor (CTGF) is triggered by Serotonin (5-HT) and Hypoxia Induced Factor 1 (HIF-1) and has been associated with tumor expansion and desmoplastic reaction in carcinoid tumors.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Kanakis G, Grimelius L, Kaltsas G, Tsolakis A,
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance, as they represent potential targets for diagnosis and treatment.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis G,
Keywords: lung, carcinoid, somatostatin ,
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Kanakis G, Grimelius L, Trigidou R, Kaltsas G, Tsolakis A,
Keywords: somatostatin receptor subtypes, dopamine receptor 2, lung carcinoids,
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: KALTSAS G
Authors: Antoniou S, Kanakis G, Zilos A, Thomas D, Tzavaris N,
Keywords: GEPNETs, temozolomide, bevacizumab, somatostatin analogue,